A rating of 79 puts Intellia Therapeutics Inc (NTLA) near the top of the Biotechnology industry according to InvestorsObserver. Intellia Therapeutics Inc's score of 79 means it scores higher than 79% of stocks in the industry. Intellia Therapeutics Inc also received an overall rating of 64, putting it above 64% of all stocks. Biotechnology is ranked 26 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 64 means the stock is more attractive than 64 percent of stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Intellia Therapeutics Inc (NTLA) stock is trading at $83.77 as of 10:40 AM on Friday, Jan 8, a rise of $6.29, or 8.12% from the previous closing price of $77.48. The stock has traded between $75.64 and $86.13 so far today. Volume today is light. So far 972,367 shares have traded compared to average volume of 1,765,098 shares.

Click Here to get the full Stock Score Report on Intellia Therapeutics Inc (NTLA) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Follow this link:
Is Intellia Therapeutics Inc (NTLA) a Winner in the Biotechnology Industry? - InvestorsObserver